Ateesha F Mohamed

Author PubWeight™ 13.53^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis.	Lung Cancer	2012	1.44
2	How does cost matter in health-care discrete-choice experiments?	Health Econ	2011	1.15
3	Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma.	J Med Econ	2012	1.08
4	Benefits, risk, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments.	AIDS Patient Care STDS	2009	0.96
5	Patient preferences for treatments to delay bone metastases.	Prostate	2014	0.89
6	Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.	Support Care Cancer	2014	0.88
7	How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?	J Rheumatol	2012	0.85
8	Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications.	Allergy Asthma Proc	2009	0.84
9	Healthy-days time equivalents for outcomes of acute rotavirus infections.	Vaccine	2011	0.81
10	Estimating importance weights for the IWQOL-Lite using conjoint analysis.	Qual Life Res	2010	0.79
11	Who pays attention in stated-choice surveys?	Health Econ	2010	0.79
12	Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection.	Patient	2012	0.79
13	Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany.	Qual Life Res	2014	0.78
14	Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment.	Psychiatr Serv	2014	0.77
15	Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease.	Alzheimer Dis Assoc Disord	2009	0.76
16	Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings.	Support Care Cancer	2008	0.75